---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-237869"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2024-10-16T23:59:59+00:00"
generated_at: "2026-05-30T13:44:29.403598+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Wave achieves first-ever therapeutic RNA editing in humans in RestorAATion-2 trial of WVE-006

## Summary
- Single 200 mg dose in first two Pi*ZZ patients produced mean total AAT ~11 µM at day 15, with edited M-AAT >60% of total.
- Wild-type M-AAT reached mean 6.9 µM at day 15, consistent with MZ genotype with low AATD risk.
- WVE-006 well-tolerated; all adverse events mild/moderate, no SAEs; multidose data expected 2025.
- Wave eligible for up to $525M milestones + royalties from GSK; Research Day Oct 30 to show pipeline.
- AATD affects ~200,000 in US/EU; current therapy limited to weekly IV augmentation (>$1.4B sales); no approved liver disease therapy.

## SEC filing metadata
- accession: 0001193125-24-237869
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2024-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312524237869/0001193125-24-237869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312524237869/d890226d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-237869
- JSON: https://secwatch.observer/filing/0001193125-24-237869.json
- Plain text: https://secwatch.observer/filing/0001193125-24-237869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.